Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.5250 (4.84%) ($5.5250 - $5.5250) on Thu. Jul. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.41% (three month average) | RSI | 75 | Latest Price | $5.5250(4.84%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 5.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 11.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(79%) ARKG(75%) IBB(69%) ARKK(68%) XLC(63%) | Factors Impacting TGTX price | TGTX will decline at least -3.705% in a week (0% probabilities). UUP(-22%) TBT(-21%) EDOC(-18%) USO(-16%) XLE(-11%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.705% (StdDev 7.41%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $4.97(11.17%) | 10 Day Moving Average | $4.68(18.06%) | 20 Day Moving Average | $4.48(23.33%) | To recent high | -43% | To recent low | 47.9% | Market Cap | $700m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |